Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-world prevalence of microsatellite instability testing and related status in women with advanced endometrial cancer in Europe

18 Apr 2024

Abstract excerpt

PURPOSE: To assess the real-world prevalence of microsatellite instability (MSI)/mismatch repair (MMR) testing and related tumor status in recurrent/advanced endometrial cancer patients in Europe. METHODS: Data were from two multi-center, retrospective patient chart review studies conducted in the United Kingdom, Germany, Italy, France and Spain: The Endometrial Cancer Health Outcomes-Europe-First-Line...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Endometrial and Cervical Cancer Treatments
Share to Genetic factors in colorectal cancer
Share to Gynecological conditions and treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38634898
DOI: 10.1007/s00404-024-07504-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-world prevalence of microsatellite instability testing and related status in women with advanced endometrial cancer in EuropePMID 38634898Read ↗

Biomarker characterization in endometrial cancer in Europe: first survey data analysis from 69 pathological academic and hospital labsSemantic proximity Read ↗

Molecular characteristics by race and ethnicity of patients with high tumor mutational burden, high microsatellite instability, and mismatch repair deficiency: Real-world data from the multi-institutional Endometrial cancer Molecularly Targeted Therapy Consortium (ECMT2).Semantic proximity Read ↗

A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instabilitySemantic proximity Read ↗

Updated evaluation of clinicopathologic landscape in histopathologic subtypes of endometrial carcinoma with MMR gene mutationSemantic proximity Read ↗

Molecular testing of endometrial carcinoma in real-world clinical practice.Semantic proximity Read ↗

The advent of immune checkpoint inhibition for the treatment of patients with primary advanced or recurrent dMMR/MSI high endometrial cancer in 2025.Semantic proximity Read ↗

Updated evaluation of clinicopathologic landscape in histopathologic subtypes of endometrial carcinoma with MMR gene mutationSemantic proximity Read ↗

Traditional and New Views on MSI-H/dMMR Endometrial Cancer.Semantic proximity Read ↗

An Analysis of Clinical, Surgical, Pathological and Molecular Characteristics of Endometrial Cancer According to Mismatch Repair Status. A Multidisciplinary Approach.Semantic proximity Read ↗

Mismatch Repair Deficiency as a Predictive and Prognostic Biomarker in Endometrial Cancer: A Review on Immunohistochemistry Staining Patterns and Clinical ImplicationsSemantic proximity Read ↗

A tale of two pathways: Review of immune checkpoint inhibitors in DNA mismatch repair‐deficient and microsatellite instability‐high endometrial cancersSemantic proximity Read ↗

Clinicopathologic features of endometrial cancer with mismatch repair deficiencySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.